Sunshine Lake Pharma breaks US barriers with historic FDA approval for LANGLARA

USA—Chinese drugmaker Sunshine Lake Pharma has secured a historic regulatory milestone after winning approval from the U.S. Food and Drug Administration for its long-acting insulin product, LANGLARA. 

This makes Sunshine Lake  the first Chinese pharmaceutical company to gain clearance for an insulin product in the United States.

The approval, announced on May 4, allows the company to market insulin glargine-aldy as an interchangeable biosimilar to Sanofi’s Lantus for both adult and pediatric patients with type 1 diabetes, as well as adults living with type 2 diabetes.

The decision positions LANGLARA as only the fourth insulin glargine product available in the US market, joining established products commercialized by Novo Nordisk, Sanofi and Eli Lilly.

More importantly, the product received the FDA’s interchangeable biosimilar designation, which allows pharmacists to substitute it for the reference product without requiring a new prescription from physicians, subject to state pharmacy laws.

This status is considered the highest regulatory standard for biosimilar medicines and is expected to support faster market uptake.

Commercial launch backed by major supply agreement

To accelerate its US entry, Sunshine Lake has partnered with Lannett Company and its newly formed biologics subsidiary, Lanexa Biologics, which will oversee commercialization and distribution.

The companies confirmed that Sunshine Lake has already secured an initial order of at least 18 million units for delivery over an 18-month period.

Lannett executives said the company is now pursuing broad formulary placement across commercial healthcare channels to ensure patient access once the product launches.

Recent statements from the partners also revealed that they are jointly advancing a short-acting insulin aspart candidate for the US market.

Years of investment drive global expansion

Sunshine Lake’s insulin program began in 2008, following earlier groundwork laid in 2005. Since then, the company has invested more than 2 billion yuan (US$280 million) in insulin development and manufacturing.

Its production facility in Yidu, China, currently manufactures more than 100 million vials annually, with expansion plans expected to increase capacity to 180 million.

FDA inspection and licensing of the site were critical to the approval process, validating the company’s manufacturing capabilities for one of the world’s most tightly regulated pharmaceutical markets.

Strategic entry into a high-value market

The US remains the world’s largest insulin market, with annual spending estimated at over US$400 billion, representing nearly 80% of global insulin sales.

Sunshine Lake previously focused on emerging markets, winning approvals in the United Arab Emirates, Algeria, and Mali while building commercial reach across Latin America, Southeast Asia, and the Middle East.

With insulin pricing facing mounting scrutiny in the US, industry analysts say lower-cost biosimilars such as LANGLARA could reshape competition.

The company is also awaiting an FDA decision on its insulin aspart biosimilar, expected in 2028, as it continues to expand its international diabetes portfolio.